Comparative Effectiveness of Adjunctive Bevacizumab for Advanced Lung Cancer: The Cancer Research Network Experience Debra P. Ritzwoller, PhD, Nikki M. Carroll, MS, Thomas Delate, PhD, Mark C. Hornbrook, PhD, Lawrence Kushi, ScD, Erin J. Aiello Bowles, MPH, Elizabeth T. Loggers, MD, PhD, Alex Menter, MD Journal of Thoracic Oncology Volume 9, Issue 5, Pages 692-701 (May 2014) DOI: 10.1097/JTO.0000000000000127 Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 1 Selection of patients for lung cancer treatment cohort. AJCC, American Joint Committee on Cancer; B, bevacizumab; CP, carboplatin-paclitaxel; NSCLC, non–small-cell lung cancer. Journal of Thoracic Oncology 2014 9, 692-701DOI: (10.1097/JTO.0000000000000127) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 2 Kaplan-Meier curves for all groups. BCP, bevacizumab plus carboplatin-paclitaxel; CP, carboplatin-paclitaxel. Journal of Thoracic Oncology 2014 9, 692-701DOI: (10.1097/JTO.0000000000000127) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions